Background/aim: The aim of this study was to identify simple and reliable factors to detect clinically insignificant prostate cancer (PC) for avoiding immediate prostate biopsies using biparametric magnetic resonance imaging (MRI), which consists of T2-weighted and diffusion-weighted imaging.
Patients And Methods: We retrospectively evaluated 427 men with suspected PC, who underwent biparametric MRI and standard 12-core transrectal prostate biopsy. MRI and prostate specific antigen density (PSAD) were analysed. To evaluate the combination of the two parameters, patients were divided into three groups (Group A: MRI negative and PSAD <0.23, Group B: MRI positive or PSAD ≥0.23, Group C: MRI positive and PSAD ≥0.23). A grade of ≥2 was defined as clinically significant PC.
Results: Clinically significant PC was detected in 46.5% of men with positive MRI findings, and 60.0% of men with PSAD ≥0.23. When combining MRI and PSAD, detection rates of clinically significant PC were 10.0%, 28.4% and 65.3% in group A, B and, C, respectively.
Conclusion: Negative biparametric MRI findings with PSAD <0.23 might be a reliable evidence for avoiding immediate prostate biopsies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.14992 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-site, multi-vendor development and validation of a deep learning model for liver stiffness prediction using abdominal biparametric MRI.
Eur Radiol
January 2025
Imaging Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Background: Chronic liver disease (CLD) is a substantial cause of morbidity and mortality worldwide. Liver stiffness, as measured by MR elastography (MRE), is well-accepted as a surrogate marker of liver fibrosis.
Purpose: To develop and validate deep learning (DL) models for predicting MRE-derived liver stiffness using routine clinical non-contrast abdominal T1-weighted (T1w) and T2-weighted (T2w) data from multiple institutions/system manufacturers in pediatric and adult patients.
Biparametric MRI-based radiomics for noninvastive discrimination of benign prostatic hyperplasia nodules (BPH) and prostate cancer nodules: a bio-centric retrospective cohort study.
Sci Rep
January 2025
Department of MRI, Zhongshan City People's Hospital, No. 2, Sunwen East Road, Shiqi District, Zhongshan, 528403, Guangdong, China.
To investigate the potential of an MRI-based radiomic model in distinguishing malignant prostate cancer (PCa) nodules from benign prostatic hyperplasia (BPH)-, as well as determining the incremental value of radiomic features to clinical variables, such as prostate-specific antigen (PSA) level and Prostate Imaging Reporting and Data System (PI-RADS) score. A restrospective analysis was performed on a total of 251 patients (training cohort, n = 119; internal validation cohort, n = 52; and external validation cohort, n = 80) with prostatic nodules who underwent biparametric MRI at two hospitals between January 2018 and December 2020. A total of 1130 radiomic features were extracted from each MRI sequence, including shape-based features, gray-level histogram-based features, texture features, and wavelet features.
View Article and Find Full Text PDFIs biparametric MRI a feasible option for detecting clinically significant prostate cancer?: A systematic review and meta-analysis.
Urol Oncol
January 2025
Research Department, Urovallarta Medical Center, Puerto Vallarta, Mexico.
Background: Multiparametric MRI (Mp-MRI) is a key tool to screen for Prostate Cancer (Pca) and Clinically Significant Prostate Cancer (CsPca). It primarily includes T2-Weighted imaging (T2w), diffusion-weighted imaging (DWI), and Dynamic Contrast-Enhanced imaging (DCE). Despite its improvements in CsPca screening, concerns about the cost-effectiveness of DCE persist due to its associated side effects, increased cost, longer acquisition time, and limitations in patients with poor kidney function.
View Article and Find Full Text PDFAn Automatic Deep-Radiomics Framework for Prostate Cancer Diagnosis and Stratification in Patients with Serum Prostate-Specific Antigen of 4.0-10.0 ng/mL: A Multicenter Retrospective Study.
Acad Radiol
January 2025
Department of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China (B.Z., F.M., X.S., S.L., Q.W.); Department of Urology, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, Guangdong 510080, China (Q.W.). Electronic address:
Rationale And Objectives: To develop an automatic deep-radiomics framework that diagnoses and stratifies prostate cancer in patients with prostate-specific antigen (PSA) levels between 4 and 10 ng/mL.
Materials And Methods: A total of 1124 patients with histological results and PSA levels between 4 and 10 ng/mL were enrolled from one public dataset and two local institutions. An nnUNet was trained for prostate masks, and a feature extraction module identified suspicious lesion masks.
Exploring the potential of the combined diagnostic model of ADC value and bp-MRI VI-RADS in the evaluation of muscle invasion in bladder Cancer.
Abdom Radiol (NY)
January 2025
Department of Radiology, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Objective: This study investigates the diagnostic value of Vesical Imaging Reporting and Data System (VI-RADS) in biparametric MRI (bp-MRI) for the detection of muscular infiltration in bladder cancer, and to investigate whether apparent diffusion coefficient (ADC) value can function as a potential indicator of bp-MRI VI-RADS for patient benefit.
Materials And Methods: This single-center retrospective study enrolled 81 patients with pathologically confirmed bladder cancer from October 2019 to November 2021. Two readers independently scored the T2-weighted images and diffusion-weighted images of each index lesion based on the VI-RADS criteria, subsequently deriving the bp-MRI VI-RADS scores.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!